The accelerated data readout is a positive catalyst; traders should position ahead of mid-May 2026 for potential volatility. A positive readout could validate the pan-RAS mechanism and significantly re-rate the stock, given ERAS-0015's potential in a high-unmet-need oncology space.
Price Chart
Executive Summary
Erasca, Inc. updated guidance, narrowing the expected timing for the Phase 1 monotherapy data readout of its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and JYP0015M101 trials to no later than mid-May 2026, an acceleration from prior 'first half of 2026' guidance. This clinical milestone is critical for validating the drug's efficacy in RAS-mutant solid tumors.
Key Facts
- Erasca narrowed the anticipated Phase 1 monotherapy data readout for ERAS-0015 to no later than mid-May 2026, up from prior guidance of first half of 2026.
- Data will come from two trials: AURORAS-1 (Erasca's trial in RAS-mutant solid tumors) and JYP0015M101 (conducted by licensor Joyo in China).
- ERAS-0015 is a pan-RAS molecular glue, a novel mechanism targeting a key oncogenic pathway with high therapeutic potential.
Financial Impact
No direct financial impact disclosed. The event is a clinical milestone that could significantly influence future valuation and partnership potential.
Risk Factors
- Clinical data may not meet efficacy or safety expectations, leading to a sharp decline.
- The accelerated timeline increases near-term event risk and stock volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-165297 |
| Document: 0001193125-26-165297-index-headers.html | 0001193125-26-165297 |
| Document: 0001193125-26-165297-index.html | 0001193125-26-165297 |
| Document: 0001193125-26-165297.txt | 0001193125-26-165297 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access